Model for high-throughput screening of multitarget drugs in chemical neurosciences: Synthesis, assay, and theoretic study of rasagiline carbamates

ACS Chemical Neuroscience

Volumn 4, Issue 10, 2013, Pages 1393-1403

  Alonso, Nerea ^a   Caamaño, Olga ^a   Romero Duran, Francisco J ^a   Luan, Feng ^b,c   D S Cordeiro, M Natália ^b   Yañez, Matilde ^a   González Díaz, Humberto ^d,e   García Mera, Xerardo ^a  

^a UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^b UNIVERSITY OF PORTO   (Portugal)

^c YANTAI UNIVERSITY   (China)

^d UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^e BASQUE FOUNDATION FOR SCIENCE   (Spain)

Author keywords

CHEMBL; drug target networks; high throughput screening; Markov chains; moving averages; multiplexing assays; multitarget QSAR; Neurodegenerative diseases; rasagiline derivatives; spectral moments

Indexed keywords

CARBAMIC ACID DERIVATIVE; DOPAMINE; GLUTAMIC ACID; INDUCIBLE NITRIC OXIDE SYNTHASE; NEUROTOXIN; RASAGILINE;

ARTICLE; DEGENERATIVE DISEASE; DOPAMINE RELEASE; DRUG DEVELOPMENT; DRUG SCREENING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; HIGH THROUGHPUT SCREENING; HUMAN; NEUROPROTECTION; NEUROSCIENCE; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; STOCHASTIC MODEL;

ANIMALS; CARBAMATES; CLINICAL TRIALS AS TOPIC; COMPUTER SIMULATION; DRUG DELIVERY SYSTEMS; GLUTAMIC ACID; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; INDANS; NEUROPROTECTIVE AGENTS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SPECTRUM ANALYSIS; STOCHASTIC PROCESSES;

EID: 84886040887     PISSN: None     EISSN: 19487193     Source Type: Journal    
DOI: 10.1021/cn400111n     Document Type: Article

References (70)

1. Bettens, K., Sleegers, K., and Van Broeckhoven, C. (2013) Genetic insights in Alzheimer's disease Lancet Neurol. 12, 92-104
2. Allegri, R. F. and Guekht, A. (2012) Cerebrolysin improves symptoms and delays progression in patients with Alzheimer's disease and vascular dementia Drugs Today 48 (Suppl. A) 25-41
3. Morales-Garcia, J. A., Susin, C., Alonso-Gil, S., Perez, D. I., Palomo, V., Perez, C., Conde, S., Santos, A., Gil, C., Martinez, A., and Perez-Castillo, A. (2013) Glycogen synthase kinase-3 inhibitors as potent therapeutic agents for the treatment of Parkinson disease ACS Chem. Neurosci. 4, 350-360
4. Ludolph, A. C., Brettschneider, J., and Weishaupt, J. H. (2012) Amyotrophic lateral sclerosis Curr. Opin. Neurol. 25, 530-535
5. Ha, A. D. and Fung, V. S. (2012) Huntington's disease Curr. Opin. Neurol. 25 (4) 491-498
6. Martin, L. J. (2012) Biology of mitochondria in neurodegenerative diseases Mol. Biol. Transl. Sci. 107, 355-415
7. Howells, D. W., Sena, E. S., O'Collins, V., and Macleod, M. R. (2012) Improving the efficiency of the development of drugs for stroke Int. J. Stroke 7, 371-377
8. Nurisso, A., Simoes-Pires, C., Martel, S., Cressend, D., Guillot, A., and Carrupt, P. A. (2012) How to increase the safety and efficacy of compounds against neurodegeneration? A multifunctional approach Chimia (Aarau) 66, 286-290
9. Gaulton, A., Bellis, L. J., Bento, A. P., Chambers, J., Davies, M., Hersey, A., Light, Y., McGlinchey, S., Michalovich, D., Al-Lazikani, B., and Overington, J. P. (2012) ChEMBL: a large-scale bioactivity database for drug discovery Nucleic Acids Res. 40, D1100-1107
10. Mok, N. Y. and Brenk, R. (2011) Mining the ChEMBL database: an efficient chemoinformatics workflow for assembling an ion channel-focused screening library J. Chem. Inf. Model. 51, 2449-2454
11. Mueller, R., Rodriguez, A. L., Dawson, E. S., Butkiewicz, M., Nguyen, T. T., Oleszkiewicz, S., Bleckmann, A., Weaver, C. D., Lindsley, C. W., Conn, P. J., and Meiler, J. (2010) Identification of MGluR Subtype 5 Potentiators Using Virtual High-Throughput Screening ACS Chem. Neurosci. 1, 288-305
12. Riera-Fernandez, P., Martin-Romalde, R., Prado-Prado, F. J., Escobar, M., Munteanu, C. R., Concu, R., Duardo-Sanchez, A., and Gonzalez-Diaz, H. (2012) From QSAR models of Drugs to Complex Networks: State-of-Art Review and Introduction of New Markov-Spectral Moments Indices Curr. Top. Med. Chem. 12, 927-60
13. Prado-Prado, F., Garcia-Mera, X., Escobar, M., Sobarzo-Sanchez, E., Yanez, M., Riera-Fernandez, P., and Gonzalez-Diaz, H. (2011) 2D MI-DRAGON: a new predictor for protein-ligands interactions and theoretic-experimental studies of US FDA drug-target network, oxoisoaporphine inhibitors for MAO-A and human parasite proteins Eur. J. Med. Chem. 46, 5838-5851
14. Helguera, A. M., Combes, R. D., Gonzalez, M. P., and Cordeiro, M. N. (2008) Applications of 2D descriptors in drug design: a DRAGON tale Curr. Top. Med. Chem. 8, 1628-1655
15. Tetko, I. V., Gasteiger, J., Todeschini, R., Mauri, A., Livingstone, D., Ertl, P., Palyulin, V. A., Radchenko, E. V., Zefirov, N. S., Makarenko, A. S., Tanchuk, V. Y., and Prokopenko, V. V. (2005) Virtual computational chemistry laboratory - design and description J. Comput.-Aided Mol. Des. 19, 453-463
16. Vilar, S., Cozza, G., and Moro, S. (2008) Medicinal chemistry and the molecular operating environment (MOE): application of QSAR and molecular docking to drug discovery Curr. Top. Med. Chem. 8, 1555-1572
17. Estrada, E. and Uriarte, E. (2001) Quantitative structure-toxicity relationships using TOPS-MODE. 1. Nitrobenzene toxicity to Tetrahymena pyriformis SAR QSAR Environ. Res. 12, 309-324
18. Estrada, E., Molina, E., and Uriarte, E. (2001) Quantitative structure-toxicity relationships using TOPS-MODE. 2. Neurotoxicity of a non-congeneric series of solvents SAR QSAR Environ. Res. 12, 445-459
19. Estrada, E., Uriarte, E., Gutierrez, Y., and Gonzalez, H. (2003) Quantitative structure-toxicity relationships using TOPS-MODE. 3. Structural factors influencing the permeability of commercial solvents through living human skin SAR QSAR Environ. Res. 14, 145-163
20. Katritzky, A. R., Perumal, S., Petrukhin, R., and Kleinpeter, E. (2001) Codessa-based theoretical QSPR model for hydantoin HPLC-RT lipophilicities J. Chem. Inf. Comput. Sci. 41, 569-574
21. Katritzky, A. R., Oliferenko, A., Lomaka, A., and Karelson, M. (2002) Six-membered cyclic ureas as HIV-1 protease inhibitors: a QSAR study based on CODESSA PRO approach. Quantitative structure-activity relationships Bioorg. Med. Chem. Lett. 12, 3453-3457
22. Katritzky, A. R., Kulshyn, O. V., Stoyanova-Slavova, I., Dobchev, D. A., Kuanar, M., Fara, D. C., and Karelson, M. (2006) Antimalarial activity: a QSAR modeling using CODESSA PRO software Bioorg. Med. Chem. 14, 2333-2357
23. Marrero-Ponce, Y., J., C.-G., Olazabal, E., Serrano, H. S., Morales, A., Castañedo, N., Ibarra-Velarde, F., Huesca-Guillen, A., Jorge, E., del Valle, A., Torrens, F., and Castro, E. A. (2004) TOMOCOMD-CARDD, a novel approach for computer-aided 'rational' drug design: I. Theoretical and experimental assessment of a promising method for computational screening and in silico design of new anthelmintic compounds J. Comput.-Aided Mol. Des. 18, 615-634
24. Marrero-Ponce, Y., Casanola-Martin, G. M., Khan, M. T., Torrens, F., Rescigno, A., and Abad, C. (2010) Ligand-Based Computer-Aided Discovery of Tyrosinase Inhibitors. Applications of the TOMOCOMD-CARDD Method to the Elucidation of New Compounds Curr. Pharm. Des. 16, 2601-2624
25. Gonzalez-Diaz, H., Duardo-Sanchez, A., Ubeira, F. M., Prado-Prado, F., Perez-Montoto, L. G., Concu, R., Podda, G., and Shen, B. (2010) Review of MARCH-INSIDE & complex networks prediction of drugs: ADMET, anti-parasite activity, metabolizing enzymes and cardiotoxicity proteome biomarkers Curr. Drug Metab. 11, 379-406
26. Gonzalez-Diaz, H., Romaris, F., Duardo-Sanchez, A., Perez-Montoto, L. G., Prado-Prado, F., Patlewicz, G., and Ubeira, F. M. (2010) Predicting drugs and proteins in parasite infections with topological indices of complex networks: theoretical backgrounds, applications, and legal issues Curr. Pharm. Des. 16, 2737-2764
27. Gonzalez-Diaz, H., Prado-Prado, F., and Ubeira, F. M. (2008) Predicting antimicrobial drugs and targets with the MARCH-INSIDE approach Curr. Top. Med. Chem. 8, 1676-1690
28. Gonzalez-Diaz, H., Prado-Prado, F., Garcia-Mera, X., Alonso, N., Abeijon, P., Caamano, O., Yanez, M., Munteanu, C. R., Pazos, A., Dea-Ayuela, M. A., Gomez-Munoz, M. T., Garijo, M. M., Sansano, J., and Ubeira, F. M. (2011) MIND-BEST: Web Server for Drugs and Target Discovery; Design, Synthesis, and Assay of MAO-B Inhibitors and Theoretical-Experimental Study of G3PDH Protein from Trichomonas gallinae J. Proteome Res. 10, 1698-1718
29. Gonzalez-Diaz, H., Prado-Prado, F., Sobarzo-Sanchez, E., Haddad, M., Maurel Chevalley, S., Valentin, A., Quetin-Leclercq, J., Dea-Ayuela, M. A., Teresa Gomez-Munos, M., Munteanu, C. R., Jose Torres-Labandeira, J., Garcia-Mera, X., Tapia, R. A., and Ubeira, F. M. (2011) NL MIND-BEST: A web server for ligands and proteins discovery-Theoretic-experimental study of proteins of Giardia lamblia and new compounds active against Plasmodium falciparum J. Theor. Biol. 276, 229-49
30. Marzaro, G., Chilin, A., Guiotto, A., Uriarte, E., Brun, P., Castagliuolo, I., Tonus, F., and Gonzalez-Diaz, H. (2011) Using the TOPS-MODE approach to fit multi-target QSAR models for tyrosine kinases inhibitors Eur. J. Med. Chem. 46, 2185-92
31. Speck-Planche, A., Kleandrova, V. V., Luan, F., and Cordeiro, M. N. (2012) A ligand-based approach for the in silico discovery of multi-target inhibitors for proteins associated with HIV infection Mol. BioSyst. 8, 2188-2196
32. Speck-Planche, A., Kleandrova, V. V., Luan, F., and Cordeiro, M. N. (2012) Chemoinformatics in anti-cancer chemotherapy: Multi-target QSAR model for the in silico discovery of anti-breast cancer agents Eur. J. Pharm. Sci. 47, 273-279
33. Speck-Planche, A., Kleandrova, V. V., and Cordeiro, M. N. (2013) Chemoinformatics for rational discovery of safe antibacterial drugs: Simultaneous predictions of biological activity against streptococci and toxicological profiles in laboratory animals Bioorg. Med. Chem. 21, 2727-32
34. Speck-Planche, A., Kleandrova, V. V., and Cordeiro, M. N. (2013) New insights toward the discovery of antibacterial agents: multi-tasking QSBER model for the simultaneous prediction of anti-tuberculosis activity and toxicological profiles of drugs Eur. J. Pharm. Sci. 48, 812-818
35. Speck-Planche, A., Kleandrova, V. V., Luan, F., and Cordeiro, M. N. (2012) Rational drug design for anti-cancer chemotherapy: multi-target QSAR models for the in silico discovery of anti-colorectal cancer agents Bioorg. Med. Chem. 20, 4848-4855
36. Speck-Planche, A., Kleandrova, V. V., Luan, F., and Cordeiro, M. N. (2011) Multi-target drug discovery in anti-cancer therapy: Fragment-based approach toward the design of potent and versatile anti-prostate cancer agents Bioorg. Med. Chem. 19, 6239-6244
37. Garcia, I., Fall, Y., Gomez, G., and Gonzalez-Diaz, H. (2011) First computational chemistry multi-target model for anti-Alzheimer, anti-parasitic, anti-fungi, and anti-bacterial activity of GSK-3 inhibitors in vitro, in vivo, and in different cellular lines Mol. Diversity 15, 561-567
38. Wiederkehr, C., Basavaraj, R., Sarrauste de Menthiere, C., Hermida, L., Koch, R., Schlecht, U., Amon, A., Brachat, S., Breitenbach, M., Briza, P., Caburet, S., Cherry, M., Davis, R., Deutschbauer, A., Dickinson, H. G., Dumitrescu, T., Fellous, M., Goldman, A., Grootegoed, J. A., Hawley, R., Ishii, R., Jegou, B., Kaufman, R. J., Klein, F., Lamb, N., Maro, B., Nasmyth, K., Nicolas, A., Orr-Weaver, T., Philippsen, P., Pineau, C., Rabitsch, K. P., Reinke, V., Roest, H., Saunders, W., Schroder, M., Schedl, T., Siep, M., Villeneuve, A., Wolgemuth, D. J., Yamamoto, M., Zickler, D., Esposito, R. E., and Primig, M. (2004) GermOnline, a cross-species community knowledgebase on germ cell differentiation Nucleic Acids Res. 32, D560-567
39. Youdim, M. B., Wadia, A., Tatton, W., and Weinstock, M. (2001) The anti-Parkinson drug rasagiline and its cholinesterase inhibitor derivatives exert neuroprotection unrelated to MAO inhibition in cell culture and in vivo Ann. N.Y. Acad. Sci. 939, 450-458
40. Gerets, H. H., Dhalluin, S., and Atienzar, F. A. (2011) Multiplexing cell viability assays Methods Mol. Biol. 740, 91-101
41. Martinez-Romero, M., Vazquez-Naya, J. M., Rabunal, J. R., Pita-Fernandez, S., Macenlle, R., Castro-Alvarino, J., Lopez-Roses, L., Ulla, J. L., Martinez-Calvo, A. V., Vazquez, S., Pereira, J., Porto-Pazos, A. B., Dorado, J., Pazos, A., and Munteanu, C. R. (2010) Artificial intelligence techniques for colorectal cancer drug metabolism: ontology and complex network Curr. Drug Metab. 11, 347-368
42. Hill, T. and Lewicki, P. (2006) STATISTICS Methods and Applications. A Comprehensive Reference for Science, Industry and Data Mining, Vol. 1, StatSoft, Tulsa.
43. Luan, F., Cordeiro, M. N., Alonso, N., Garcia-Mera, X., Caamano, O., Romero-Duran, F. J., Yanez, M., and Gonzalez-Diaz, H. (2013) TOPS-MODE model of multiplexing neuroprotective effects of drugs and experimental-theoretic study of new 1,3-rasagiline derivatives potentially useful in neurodegenerative diseases Bioorg. Med. Chem. 21, 1870-1879
44. Garcia-Garcia, A., Galvez, J., de Julian-Ortiz, J. V., Garcia-Domenech, R., Munoz, C., Guna, R., and Borras, R. (2004) New agents active against Mycobacterium avium complex selected by molecular topology: a virtual screening method J. Antimicrob. Chemother. 53, 65-73
45. Marrero-Ponce, Y., Castillo-Garit, J. A., Olazabal, E., Serrano, H. S., Morales, A., Castanedo, N., Ibarra-Velarde, F., Huesca-Guillen, A., Sanchez, A. M., Torrens, F., and Castro, E. A. (2005) Atom, atom-type and total molecular linear indices as a promising approach for bioorganic and medicinal chemistry: theoretical and experimental assessment of a novel method for virtual screening and rational design of new lead anthelmintic Bioorg. Med. Chem. 13, 1005-1020
46. Marrero-Ponce, Y., Machado-Tugores, Y., Pereira, D. M., Escario, J. A., Barrio, A. G., Nogal-Ruiz, J. J., Ochoa, C., Aran, V. J., Martinez-Fernandez, A. R., Sanchez, R. N., Montero-Torres, A., Torrens, F., and Meneses-Marcel, A. (2005) A computer-based approach to the rational discovery of new trichomonacidal drugs by atom-type linear indices Curr. Drug Discovery Technol. 2, 245-265
47. Casanola-Martin, G. M., Marrero-Ponce, Y., Khan, M. T., Ather, A., Sultan, S., Torrens, F., and Rotondo, R. (2007) TOMOCOMD-CARDD descriptors-based virtual screening of tyrosinase inhibitors: evaluation of different classification model combinations using bond-based linear indices Bioorg. Med. Chem. 15, 1483-1503
48. Casanola-Martin, G. M., Marrero-Ponce, Y., Tareq Hassan Khan, M., Torrens, F., Perez-Gimenez, F., and Rescigno, A. (2008) Atom- and bond-based 2D TOMOCOMD-CARDD approach and ligand-based virtual screening for the drug discovery of new tyrosinase inhibitors J. Biomol. Screening 13, 1014-1024
49. Casanola-Martin, G. M., Marrero-Ponce, Y., Khan, M. T., Khan, S. B., Torrens, F., Perez-Jimenez, F., Rescigno, A., and Abad, C. (2010) Bond-based 2D quadratic fingerprints in QSAR studies: virtual and in vitro tyrosinase inhibitory activity elucidation Chem. Biol. Drug Des. 76, 538-545
50. Rodriguez-Soca, Y., Munteanu, C. R., Dorado, J., Pazos, A., Prado-Prado, F. J., and Gonzalez-Diaz, H. (2010) Trypano-PPI: a web server for prediction of unique targets in trypanosome proteome by using electrostatic parameters of protein-protein interactions J. Proteome Res. 9, 1182-1190
51. Gonzalez-Diaz, H., Muino, L., Anadon, A. M., Romaris, F., Prado-Prado, F. J., Munteanu, C. R., Dorado, J., Pazos Sierra, A., Mezo, M., Gonzalez-Warleta, M., Garate, T., and Ubeira, F. M. (2011) MISS-Prot: web server for self/non-self discrimination of protein residue networks in parasites; theory and experiments in Fasciola peptides and Anisakis allergens Mol BioSyst. 7, 1938-1955
52. Wang, M. D., Huang, Y., Zhang, G. P., Mao, L., Xia, Y. P., Mei, Y. W., and Hu, B. (2012) Exendin-4 improved rat cortical neuron survival under oxygen/glucose deprivation through PKA pathway Neuroscience 226, 388-96
53. Ryu, S., Shin, J. S., Cho, Y. W., Kim, H. K., Paik, S. H., Lee, J. H., Chi, Y. H., Kim, J. H., and Lee, K. T. (2013) Fimasartan, Anti-hypertension Drug, Suppressed Inducible Nitric Oxide Synthase Expressions via Nuclear Factor-Kappa B and Activator Protein-1 Inactivation Biol. Pharm. Bull. 36, 467-474
54. Lorrio, S., Gomez-Rangel, V., Negredo, P., Egea, J., Leon, R., Romero, A., Dal-Cim, T., Villarroya, M., Rodriguez-Franco, M. I., Conde, S., Arce, M. P., Roda, J. M., Garcia, A. G., and Lopez, M. G. (2013) Novel multitarget ligand ITH33/IQM9.21 provides neuroprotection in in vitro and in vivo models related to brain ischemia Neuropharmacology 67, 403-411
55. Youdim, M. B. (2013) Multi target neuroprotective and neurorestorative anti-Parkinson and anti-Alzheimer drugs ladostigil and M30 derived from rasagiline Exp. Neurobiol. 22, 1-10
56. Conn, P. J., Lindsley, C. W., and Jones, C. K. (2009) Activation of metabotropic glutamate receptors as a novel approach for the treatment of schizophrenia Trends Pharmacol. Sci. 30, 25-31
57. Conn, P. J., Jones, C. K., and Lindsley, C. W. (2009) Subtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disorders Trends Pharmacol. Sci. 30, 148-155
58. Conn, P. J., Christopoulos, A., and Lindsley, C. W. (2009) Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders Nat. Rev. Drug Discovery 8, 41-54
59. Engers, D. W., Niswender, C. M., Weaver, C. D., Jadhav, S., Menon, U. N., Zamorano, R., Conn, P. J., Lindsley, C. W., and Hopkins, C. R. (2009) Synthesis and evaluation of a series of heterobiarylamides that are centrally penetrant mGluR 4 (mGluR4) positive allosteric modulators (PAMs) J. Med. Chem. 52, 4115-4118
60. Csermely, P., Nussinov, R., and Szilágyi, A. (2013) From allosteric drugs to allo-network drugs: state of the art and trends of design, synthesis and computational methods Curr. Top. Med. Chem. 13, 2-4
61. Szilágyi, A., Nussinov, R., and Csermely, P. (2013) Allo-network drugs: extension of the allosteric drug concept to protein-protein interaction and signaling networks Curr. Top. Med. Chem. 13, 64-77
62. Menniti, F. S., Lindsley, C. W., Conn, P. J., Pandit, J., Zagouras, P., and Volkmann, R. A. (2013) Allosteric modulators for the treatment of schizophrenia: targeting glutamatergic networks Curr. Top. Med. Chem. 13, 26-54
63. Csermely, P., Korcsmáros, T., Kiss, H. J., London, G., and Nussinov, R. (2013) Structure and dynamics of molecular networks: A novel paradigm of drug discovery: A comprehensive review Pharmacol Ther. 138, 333-408
64. Farkas, I. J., Korcsmáros, T., Kovács, I. A., Mihalik, á, Palotai, R., Simkó, G. I., Szalay, K. Z., Szalay-Beko, M., Vellai, T., Wang, S., and Csermely, P. (2011) Network-based tools for the identification of novel drug targets Sci. Signaling 4, pt3
65. Nussinov, R., Tsai, C. J., and Csermely, P. (2011) Allo-network drugs: harnessing allostery in cellular networks Trends Pharmacol. Sci. 32, 686-693
66. Heikamp, K. and Bajorath, J. (2011) Large-scale similarity search profiling of ChEMBL compound data sets J. Chem. Inf. Model. 51, 1831-1839
67. Tenorio-Borroto, E., Penuelas Rivas, C. G., Vasquez Chagoyan, J. C., Castanedo, N., Prado-Prado, F. J., Garcia-Mera, X., and Gonzalez-Diaz, H. (2012) ANN multiplexing model of drugs effect on macrophages; theoretical and flow cytometry study on the cytotoxicity of the anti-microbial drug G1 in spleen Bioorg. Med. Chem. 20, 6181-6194
68. Speck-Planche, A., Kleandrova, V. V., Luan, F., and Cordeiro, M. N. (2011) Multi-target drug discovery in anti-cancer therapy: fragment-based approach toward the design of potent and versatile anti-prostate cancer agents Bioorg. Med. Chem. 19, 6239-6244
69. StatSoft Inc. (2002) STATISTICA (data analysis software system), version 6.0, www.statsoft.com, Statsoft Inc., Tulsa, OK.
70. Mosmann, T. (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays J. Immunol. Methods 65, 55-63